Reacción a "Genetically modified pigs developed to resist classical swine fever infection"

The article describes the generation of pigs with mutations in the DNAJC14 gene, a gene involved in pestivirus replication. Previous studies in cell cultures, conducted by researchers at the University of Lübeck (Germany), had shown that DNAJC14 plays an essential role in the replication of these viruses. In this work, in collaboration with the team at the Roslin Institute (Edinburgh), edited animals were generated by microinjecting zygote-stage embryos with the CRISPR/Cas9 system, with the aim of introducing a specific point mutation (W576A) into this gene.

The results show that these animals, and the cells derived from them, are resistant to infection with classical swine fever virus, and that their cell cultures also exhibit resistance to bovine viral diarrhea virus (BVDV).

Overall, this is a high-quality article, both in its experimental design and in the clarity of the results and their practical implications. It confirms the usefulness of gene editing as a tool for generating viral resistance in production animals, which has enormous health, animal welfare, and economic implications. Classical swine fever remains one of the most devastating diseases in the swine sector, causing high mortality, production losses, increased antibiotic use, and impacts on food safety due to the reduced availability of high-quality animal proteins.

This work is part of a growing line of evidence showing that gene editing targeting host genes can confer resistance to high-impact viruses. Previously, resistance to the porcine reproductive and respiratory syndrome (PRRS) virus through mutation of the CD163 gene, as well as partial resistance to the swine influenza virus, had been described. This new study significantly expands the repertoire of target genes and demonstrates the versatility and robustness of the gene editing strategy for controlling infectious diseases.

At the University of Murcia, we are working on the creation of animals resistant to two or more diseases. To date, we have obtained embryos and piglets with mutations in genes related to resistance to PRRS and influenza, both of which have a major impact on the swine sector and, in the case of influenza, also on human health.

This study was funded by a leading multinational swine genetics company (Genus/PIC), a pioneer in the commercial use of gene-edited animals. In fact, Genus/PIC has already obtained FDA approval for the commercial use of CD163KO pigs, resistant to PRRS. The DNAJC14 model described in the article has been patented by the University of Edinburgh (PCT/GB2025/050430), which will allow for its potential transfer and industrial licensing.

Unfortunately, European authorities have not yet authorized the use of gene-edited animals, despite the EFSA issuing reports stating that gene editing is not equivalent to transgenesis and that its risk is comparable to that of natural reproduction. This situation, coupled with the lack of business support and the limited patent protection available to academic groups, is hindering the development of these models in Spain. The lack of resources to maintain qualified personnel remains one of the main structural problems facing Spanish science.

This is preliminary work that must be complemented with additional studies evaluating potential off-target effects, as well as impacts on the growth, development, and productive and reproductive characteristics of the animals. These analyses will be essential to confirm the safety and productive viability of the generated models, as has been previously done with CD163KO pigs.

In summary, this article represents a major, high-quality scientific breakthrough, consolidating gene editing as a realistic and effective tool for controlling infectious diseases in livestock, allowing for simultaneous improvements in animal health and productivity.